Mandate

Vinge has advised Azelio in connection with its rights issue

Vinge has advised Azelio AB (publ) on a fully guaranteed rights issue, which will provide Azelio with issue proceeds amounting to approximately SEK 300 million before deduction of transaction costs.

The new shares and warrants issued by reason of the rights issue are expected to be admitted to trading on Nasdaq First North Growth Market on 31 October 2022.

Azelio is a public Swedish company, specializing in in energy storage with electricity and heat production. Azelio’s system (“TES.POD “) for renewable, Stirling-based electricity production and heat production is based on continuous technological development and refinement. The technology makes the energy dispatchable, enabling renewable energy to be made available around-the-clock.

Azelio’s shares are listed on Nasdaq First North Growth Market.

Vinge’s team consisted primarily of David Andersson, William Kåge, Joel Magnusson, Benjamin Vafaeian and Joacim Malmqvist.

 

Related

Vinge advises Trianon in connection with directed share issue and tender offer for subordinated sustainable capital securities

Vinge advises Fastighets Aktiebolaget Trianon (publ) in connection with a directed share issue of SEK 184 million and a tender offer for outstanding subordinated perpetual floating rate callable sustainable capital securities.
April 19, 2024

Vinge advises Blackstone in connection with its investment in Winthrop Technologies

Vinge, as local Swedish counsel, advised Blackstone Tactical Opportunities and affiliated funds (“Blackstone”) in connection with a strategic partnership with Winthrop Technologies Limited (“Winthrop Technologies”).
April 17, 2024

Vinge has advised Hansa Biopharma in connection with a directed share issue of SEK 372 million

Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of SEK 372 million before transaction costs. Hansa Biopharma is a commercial-stage biopharmaceutical company pioneering the development and commercialization of innovative, lifesaving and life altering treatments for patients with rare immunological conditions. Hansa Biopharma’s ordinary share is listed on Nasdaq Stockholm.
April 16, 2024